Overview

Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer

Status:
Completed

Trial end date:
2016-10-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is Examination of the superiority of a combination of vinorelbine with the mTOR Inhibitor Everolimus vs. vinorelbine monotherapy for second-line treatment in advanced breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

AIO-Studien-gGmbH

Collaborators:

iOMEDICO AG
Novartis Pharmaceuticals

Treatments:

Everolimus
Sirolimus
Vinblastine
Vinorelbine